Latest Industry Insights

As researchers explore therapeutic strategies for more complex and heterogeneous diseases the need for more physiologically relevant models has never been greater. Researchers are increasingly looking to 3D cell cultures, spheroids, organoids and microtissues to bridge the gap between 2D cell cultures and in vivo animal models.

We spoke to Dr Jonathan Jones from Waters Corporation, to learn more about the new initiative that they and Swansea University are leading to give students hands-on experience of mass spectrometry.

We recently spoke to Bruker’s JoAnne Bruno, Director Sales and Marketing and Sven Malik, Senior Application Specialist, to learn how surface plasmon resonance can be used to investigate the binding properties of small molecules, and how it can help researchers make better decisions about drug candidates and support efforts to design new molecules.

Genedata’s Screener software aims to streamline data workflows and make analysis easier. We caught up with Dr. Oliver Leven, Head of Genedata Screener Business Europe, to discuss how we researchers can make data more standardized, accessible and shareable whilst not compromising on security and integrity.

Having too much data sounds like a nice problem to have. But Next Generation Sequencing (NGS) data’s ubiquity poses challenges as well as opportunities for geneticists. Quick, accurate and reliable workflows are top of the average geneticist’s wishlist. We caught up with OGT’s Dave Cook to discuss the challenges of NGS data, and how software can make things simpler.

Robust data management is integral to both academic researchers and scientists in the pharmaceutical industry, especially for those working with bioprocessing workflows. In this blog, Thermo Fisher Scientific’s Karen Velardi explains how the introduction of digital science solutions to the modern lab is transforming bioprocessing workflows by providing scientists with full control over procedures, data integrity and compliance

A clinical trial has been launched to identify urine-based biomarkers which indicate lung flare-ups in cystic fibrosis. Researchers believe point-of-care monitoring will help people get treatment faster, improve patient outcomes and reduce healthcare costs.

No scientist is an island, and to maximize the power of data, researchers have to share their results with the wider community. Now, GenScript's launch of its MolecularCloud platform suggests sharing plasmid data may become easier than ever before.

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners recently announced the launch of Magnolia Neurosciences Corporation – a biopharmaceutical company advancing a new class of neuroprotective medicines.

How do you start, grow and run a successful life science company? To find out we spoke to Dr Yichen Shi, CEO of Axol Bioscience.